BACKGROUND AND OBJECTIVES: Cystatin C is used increasingly as a biomarker of renal function; however, cystatin C assays are not standardized. Our objective was to compare cystatin C results within the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study over time and in repeated measures to evaluate for assay drift. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum samples were obtained at baseline (visit 1 [V1], 2000 to 2002) and follow-up (visit 2 [V2], 2003 to 2005; visit 3 [V3], 2006 to 2008) and were assayed in 2006 (V1), 2007 to 2008 (V2), and 2010 (V3) in the same laboratory. RESULTS: Mean cystatin C levels measured using the Dade-Behring assay decreased over time in subjects, with measures at all three visits (V1: 0.80 ± 0.19 [0.42 to 3.41], V2: 0.75 ± 0.22 [0.39 to 3.77], and V3: 0.69 ± 0.22 [0.39 to 3.79]). Cystatin C values were lower in V1 and V2 samples remeasured in 2010 (mean differences -0.13 ± 0.04 and -0.08 ± 0.04, P < 0.0001 for both). Correlations for original and re-run values were strong for V1 (r = 0.99) and V2 (r = 0.99). Deming regression equations and Bland-Altman plots suggest a systematic shift in the values over time. CONCLUSIONS: Systematic shifts in cystatin C levels, which can be corrected by regression adjustment, occurred in our laboratory in samples measured in 2006 and 2007 to 2008 as compared with 2010. Assay standardization and measurement reliability for cystatin C must be addressed.
BACKGROUND AND OBJECTIVES:Cystatin C is used increasingly as a biomarker of renal function; however, cystatin C assays are not standardized. Our objective was to compare cystatin C results within the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study over time and in repeated measures to evaluate for assay drift. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum samples were obtained at baseline (visit 1 [V1], 2000 to 2002) and follow-up (visit 2 [V2], 2003 to 2005; visit 3 [V3], 2006 to 2008) and were assayed in 2006 (V1), 2007 to 2008 (V2), and 2010 (V3) in the same laboratory. RESULTS: Mean cystatin C levels measured using the Dade-Behring assay decreased over time in subjects, with measures at all three visits (V1: 0.80 ± 0.19 [0.42 to 3.41], V2: 0.75 ± 0.22 [0.39 to 3.77], and V3: 0.69 ± 0.22 [0.39 to 3.79]). Cystatin C values were lower in V1 and V2 samples remeasured in 2010 (mean differences -0.13 ± 0.04 and -0.08 ± 0.04, P < 0.0001 for both). Correlations for original and re-run values were strong for V1 (r = 0.99) and V2 (r = 0.99). Deming regression equations and Bland-Altman plots suggest a systematic shift in the values over time. CONCLUSIONS: Systematic shifts in cystatin C levels, which can be corrected by regression adjustment, occurred in our laboratory in samples measured in 2006 and 2007 to 2008 as compared with 2010. Assay standardization and measurement reliability for cystatin C must be addressed.
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: David M Maahs; Gregory L Kinney; Paul Wadwa; Janet K Snell-Bergeon; Dana Dabelea; John Hokanson; James Ehrlich; Satish Garg; Robert H Eckel; Marian J Rewers Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112
Authors: Dana Dabelea; Gregory Kinney; Janet K Snell-Bergeon; John E Hokanson; Robert H Eckel; James Ehrlich; Satish Garg; Richard F Hamman; Marian Rewers Journal: Diabetes Date: 2003-11 Impact factor: 9.461
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: P Bjornstad; T Costacou; R G Miller; D M Maahs; M J Rewers; T J Orchard; J K Snell-Bergeon Journal: Diabet Med Date: 2017-08-14 Impact factor: 4.359
Authors: F Iliadis; T Didangelos; A Ntemka; A Makedou; E Moralidis; A Gotzamani-Psarakou; T Kouloukourgiotou; D Grekas Journal: Diabetologia Date: 2011-09-23 Impact factor: 10.122
Authors: Petter Bjornstad; David M Maahs; Marian Rewers; Richard J Johnson; Janet K Snell-Bergeon Journal: J Diabetes Complications Date: 2014-07-04 Impact factor: 2.852
Authors: Petter Bjornstad; David M Maahs; Christopher J Rivard; Laura Pyle; Marian Rewers; Richard J Johnson; Janet K Snell-Bergeon Journal: Acta Diabetol Date: 2014-06-15 Impact factor: 4.280
Authors: Bas C T van Bussel; Isabel Ferreira; Marjo P H van de Waarenburg; Marleen M J van Greevenbroek; Carla J H van der Kallen; Ronald M A Henry; Edith J M Feskens; Coen D A Stehouwer; Casper G Schalkwijk Journal: PLoS One Date: 2013-03-05 Impact factor: 3.240
Authors: Jay L Koyner; Amit X Garg; Michael G Shlipak; Uptal D Patel; Kyaw Sint; Kwangik Hong; Prasad Devarajan; Charles L Edelstein; Michael Zappitelli; Heather Thiessen-Philbrook; Chirag R Parikh Journal: Am J Kidney Dis Date: 2013-01-16 Impact factor: 8.860